BB Biotech

BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and since 2000 on the Italian Borsa Italiana.[2]

BB Biotech AG
TypeAktiengesellschaft
SIX: BION, FWB: BBZA
IndustryInvestments
FoundedSchaffhausen, Switzerland (9 November 1993 (9 November 1993))
HeadquartersKüsnacht, Switzerland
Key people
Erich Hunziker (Chairman)
ProductsInvestment in biotechnology companies
CHF 677 million (2019)[1]
Total assetsCHF 3.393 billion (2019)[1]
Websitewww.bbbiotech.ch

In December 2016 the company launched BB Healthcare Trust, an investment trust focused on biotech companies.[3]

As of December 31, 2019 the seven core investments in the BB Biotech portfolio were: Ionis Pharmaceuticals (13.5% of the BB Biotech Portfolio); Neurocrine Biosciences (9.5%); Incyte (8.2%); Vertex Pharmaceuticals (7.5%), Esperion Therapeutics (6.1%); Agios Pharmaceuticals (5.1%), Alnylam Pharmaceuticals (5.1%)[4]

Company Figures

Company figures are as follows:[5][6]

(figures in millions CHF) 2019 2018 2017 2016 2015
Profit/(loss) 677.4 (471.3) 687.5 (802.1) 652.8
Net Asset Value 3393.0 2884.5 3538.7 3003.0 3978.2
Market capitalization 3670.3 3235.4 3576.1 3052.5 3463.2

References
  1. "Annual Report 2019" (PDF). BB Biotech. Retrieved 3 June 2020.
  2. "BB Biotech". Borsa Italiana. Retrieved 3 June 2020.
  3. "Star BB Biotech manager steps back from Healthcare trust". City Wire. 25 March 2019. Retrieved 3 June 2019.
  4. "BB Biotech Portfolio". BB Biotech. 11 March 2020.
  5. finanzen.net Retrieved 1st of January 2016.
  6. "BB Biotech - Facts & Figures". BB Biotech. 11 March 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.